Introduction: Radiation recall, which was first described in 1959, remains a rare and erratic inflammatory phenomenon that manifests in previously irradiated areas after the subsequent administration of chemotherapeutic agents [1]. Anthracyclines, taxanes, antimetabolites, and topoisomerase inhibitors have all been associated with radiation recall [2], as have specific agents such as dabrafenib, pazopanib, sorafenib, and trastuzumab [3–5]. The interval between the cessation of radiation and manifestation of the inflammation can range from a few days to 15 years [6].
Date:
2019-12
Relation:
International Journal of Hyperthermia. 2019 Dec;36(1):1185-1188.
